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Healthcare resource utilization (HCRU) in hospitalized febrile neutropenia (FN) patients treated with chemotherapy for solid tumors (ST) and hematological malignancies (HM) in Bulgaria
STUDY DESIGN
• This was a multicenter, retrospective, observational, non-interventional study based on a cohort chart review. All eligible patients were selected on a consecutive basis starting with the most recent (i.e. patients who completed their chemotherapy by September 2012). This study was conducted without any study specific change to the clinical management of patients; • Adult patients (≥18 years) diagnosed with solid tumors or hematological malignancies at any stage and ECOG performance status, who were admitted to hospitals and experienced at least one confirmed FN event, were enrolled in the study; • Observation started at the beginning of the cycle in which the first FN occurred (index cycle) until the end of patients' respective regimen of chemotherapy treatment or until the patient died or was lost to follow-up; HCRU data was summarized for index cycle, post-index cycles (subsequent cycles cumulatively), and overall observation period;
• Using hospital admission data, neutropenia complications were identified on the basis of hospital admissions with a primary or secondary diagnosis of neutropenia; • FN was defined as an absolute neutrophil count (ANC) of : <0.5 x 10 9 /L, or <1.0 x 10 9 /L predicted to fall below 0.5 x 10 9 /L within 48 h, with fever or clinical signs of sepsis (infection). Fever was defined per hospital diagnosis. N, number of subjects; n, number of non-missing values; percentages are based on the number of all enrolled patients.
• All patients were treated in urban centers, with 80% in university hospitals;
• 67 patients (43%) had 1-2 chemotherapy cycles administered, 40 patients (26%) -3-4 chemotherapy cycles, and 49 patients (31%) ->4 chemotherapy cycles.
RESULTS
Table 3. G-CSF use in the index cycles (FAS)
Note: percentages are based on the number of patients in FAS. Note: Assignment of patients to the categories primary prophylaxis, secondary prophylaxis or treatment was done by the investigators and multiple assignments were possible. In patients receiving G-CSF in different settings within the index cycle, i.e. any form of prophylaxis plus treatment, a hierarchical approach was followed as the best estimate of G-CSF support for a subject, classing the patient in the respective prophylaxis category, but summarizing the entire G-CSF usage (prophylaxis plus treatment) within that cycle. • In the post-index cycles the use of anti-infectives was much lower than in the index cycles (7% of patients).
RESULTS
• In total, 156 patients with solid tumors and hematological malignancies hospitalized for FN in the period of January 2009 to September 2012 from 11 Bulgarian centers were enrolled into this study and included in FAS; • 64 (41%) patients had solid tumors, and 92 (59%) patients had hematological malignancies; • Informed consent was not required.
The majority of patients received G-CSF as treatment and not as a prophylaxis;
• Use of G-CSF as primary prophylaxis was higher in patients with hematological malignancies than with solid tumors; • G-CSF use was greatly reduced in post-index cycles compared to the index cycle (~22% of patients).
This analysis was sponsored by Amgen (Europe) GmbH
• The maximum number of FN episodes was 7 (in a patient with hematological malignancies); • FN was most common in cycle 1 (56%); the first FN occurred as late as cycle 8; • There was no clear trend for earlier or later occurrence of FN in solid tumors vs hematological malignancies. • FN-specific HCRU parameters included infection prophylaxis and treatments, G-CSF use, other prophylactic medication, specific interventions and investigations, and FN-related hospitalizations were analyzed; • G-CSF use groups were defined as primary prophylaxis, secondary prophylaxis or treatment according to the value entered in the Setting field on the eCRF G-CSF page; • The number and percentage of subjects with adverse drug reactions (ADRs) and fatal ADRs was collected for each related product: pegfilgrasim, filgrastim, or other Amgen products; • Data summaries were split by cancer type: solid tumors and hematological malignancies.
ADRs:
• No patients from Bulgaria experienced ADRs related to Amgen product.
Deaths:
• The total number of deaths during the retrospective observation period was 17 (11%); • The percentage of patients who died was equal between the tumor types; • The main reasons for death* were FN-related, 8 (47%), or cancerrelated, 5 (29%); the percentage of deaths which were FN-related was higher in solid tumors than in hematological malignancies (86% vs 20% respectively); • Five patients with hematological malignancies died from the following reasons: pulmonary and cardiovascular multiorgan insufficiency, sepsis, stroke, and suspected brain hemorrhage, due to post chemotherapy thrombocytopenia (1 patients (10%) from each reason).
*-percentages are based on the number of patients who died. Number of FN episodes and cycle of occurrence are summarized in Table 6 .
The most frequent concomitant diseases:
• 21 patients (14%) had cardio-vascular disease;
• 5 patients (3%) had diabetes. The most frequent malignancy types: Solid tumors: malignant neoplasm of breast (15 patients (23%)), malignant neoplasm of colon (7 patients (11%)), malignant neoplasm of bronchus and lung NSCLC and malignant neoplasm of bronchus and lung SCLC (6 patients (9%) respectively); Hematological malignancies: myeloid leukemia (27 patients (29%)), nonfollicular lymphoma (22 patients (24%)), Hodgkin's disease (15 patients (16%)), other and unspecified types of non-Hodgkin's lymphoma (11 patients (12%)). • In post-index cycles, the number of investigations and interventions was reduced compared to index cycles (140 vs 531 and 69 vs 416, respectively).
METHODS
Hospitalizations
• As per inclusion criteria, all participating patients experienced at least one FN-related hospitalization; • Patients with hematological malignancies had longer hospital stays and more hospitalizations than patients with solid tumors (Figure 1 and 2) . • 72 patients (46%) had surgeries, 35 patients (22%) had chemotherapies, and 16 patients (10%) had radiotherapy.
• The mean (SD) number of FN-related hospital days was 7.2 (4.78 ).
The most frequently conducted investigations:
• Blood tests 116 (74%) patients); imaging examinations (27 (17%) patients); blood culture and sensitivity (21 (14%) patients) ;
The most frequently conducted interventions:
• Administration of IV fluids (93 (60%) patients); RBC transfusions (36 (23%) patients); 
Study Limitations
Due to the retrospective nature of the study, investigators had to rely on the data for important outcomes to be routinely and accurately collected in medical records, which may not always have been the case, potentially introducing underestimation of these outcomes.
